Global Novel Drug Delivery Systems in Cancer Therapy Market by Product (Embolization Particles, Nanoparticles) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

In 2016, the global market for novel drug delivery systems in cancer treatment was valued at USD 4.31 trillion. It is expected to grow at a 22.9% CAGR during the forecast period. This market is driven by the increasing incidence of cancer worldwide, increased awareness about alternative treatment options, improved reimbursement in developed countries, and funding for research. Market growth will also be boosted by the use of Nanoparticles for treating cancers.

Investments in R&D for novel drug delivery methods are key players in this market. Celgene Corporation, for example, increased its R&D spending from USD 3697.3 million in 2015 and USD 4470.1 million in 2016. This was to expand product range and obtain regulatory approvals for new products.

The market for novel drug delivery systems in the cancer therapy market will be affected by a lack of awareness and inadequate funding. Research projects in cancer require significant investment and funding. While developed countries such as the U.S., U.K. and Germany have numerous organizations that fund new technologies and research projects in other countries such as Brazil, Mexico and India, they are not adequately funded. These countries are also very unaware of alternative treatments and new technologies.

Product Insights

The market can be divided into embolization and nanoparticles based on the type of new drug delivery system. The market is further divided into nanoparticles: liposomes; polymers; micelles; and other nanoparticles. The nanoparticles market segment held the largest share of the total market in 2016, and will continue to dominate the market for novel drug delivery systems in cancer treatment throughout the forecast period.

The unique use of nanoparticles in cancer treatment is a novel approach. They protect the drug from chemical and enzymatic decay by encapsulating it. The use of nanoparticles for drug delivery has long circulation half-lives. They also reduce side effects and improve pharmacokinetics. They also have enhanced permeability which makes it possible to deliver drugs efficiently to cancer tissues. The use of nanoparticles to deliver drugs to cancer tissues is a promising alternative to traditional chemotherapy.

To increase drug efficacy, DNA delivery and target and targeting, nanoparticle delivery systems like micelles and liposomes are frequently used. New drug delivery systems are in high demand due to the constant improvement of the therapeutic properties drugs. By type, liposomes dominated the nanoparticles segment in 2016. This segment is expected to grow at a fastest rate over the forecast period.

Tumor embolization refers to the blocking of blood vessels that supply oxygen or blood to tumors. Further, the embolization particles section can be classified into PVA particles and drug-eluting beads. These particles are injected into vessels that supply blood to cancer cells. This allows for easy surgical removal of cancer cells due to reduced blood loss.

Regional Insights

With a 36.8% revenue share, North America was the dominant market in 2016. The market's growth is due to several factors, including an increase in research into new therapies, increased budget for drug discovery, increasing awareness through marketing and promotional activities by manufacturers, and rising incidence of cancer. Market growth will be boosted by FDA approvals of NDDS commercially and an increase in clinical trials.

The Asia Pacific market is expected to grow at the fastest pace during the forecast period for novel drug delivery system in cancer therapy. This is due to the rising incidence of cancer in Japan and China, increased geriatric population in Japan and collaborations between U.S.-China to strengthen cancer research. It also reflects an increase in awareness about innovative therapies in Asia Pacific. Market growth will also be boosted by increased research activity in Asia Pacific countries during the forecast period.

In 2016, Europe accounted for the second largest share of this market. Due to the large number of patients with cancer, increased research funding, awareness of new therapies and high healthcare spending in Europe, the European market is expected grow rapidly.

Market Share Insights & Key Companies

Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., GALEN, Merrimack Pharmaceuticals, Inc., Shire; Samyang Biopharmaceuticals Corporation, Celgene Corporation, Spectrum Pharmaceuticals, Inc., and BTG are some of the major players in the market for novel drug delivery system in cancer therapy. To increase their market share, key strategies include frequent product launches, geographic expansions and distribution agreements.

Market Report Scope: Novel Drug Delivery Systems in Cancer Therapy

The Report Covers Certain Segments

This report provides industry trends analysis and forecasts for revenue growth from 2014-2025. Grand View Research, Inc. analyzed the cancer therapy market for novel drug delivery systems (NDDS), based on product and location.

• Product Outlook (Revenue USD Million, 2014-2025)

  • Nanoparticles

    • Liposomes

    • Polymers

    • Micelles

    • Other nanoparticles

  • Embolization particles

    • PVA particles

    • Beads that can be used to inject drugs

    • Liquid emboli

    • Other embolization particles

• Regional Outlook (Revenue USD Million, 2014-2025)

  • North America

    • The U.S.

    • Canada

  • Europe

    • Germany

    • The U.K.

  • Asia Pacific

    • Japan

    • China

  • Latin America

    • Brazil

    • Mexico

  • MEA

    • South Africa

These are the most frequently asked questions about this report

b. Global market for novel drug delivery systems for cancer therapy was valued at USD 7.3 billion in 2019. It is projected to grow to USD 8.9 billion by 2020.

b. Global novel drug delivery systems for cancer therapy are expected to grow at a compound annual rate of 22.9% between 2017 and 2025, to reach USD 26.9 billion by 2025.

b. With a 37.21% share in 2019, North America was the dominant market for novel drug delivery systems in cancer treatment. This can be attributed to an increase in research and development activities, a higher budget for novel drug discovery and increased awareness through marketing and promotional activities by manufacturers and an increase of the incidence of cancer.

b. Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., GALEN, Merrimack Pharmaceuticals, Inc., Shire; Samyang Biopharmaceuticals Corporation, Celgene Corporation, Spectrum Pharmaceuticals, Inc., and BTG are some of the key players in the new drug delivery system in cancer therapy market.

b. The market is driven by the increasing incidence of cancer worldwide, increased awareness about alternative treatments, and favorable reimbursement arrangements in developed countries.

Up Market Research published a new report titled “Novel Drug Delivery Systems in Cancer Therapy Market research report which is segmented by Product (Embolization Particles, Nanoparticles), By Players/Companies FDA approvals for commercial availability of NDDS and rise in number of clinical trials for this therapy are expected to boost market growth in this region, increase in budget for novel drug discovery, increasing incidence of cancer In addition, growing awareness due to marketing and promotional activities of manufacturers, rise in the number of research activities for new therapies”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Novel Drug Delivery Systems in Cancer Therapy Market Report Segments:

The market is segmented by Product (Embolization Particles, Nanoparticles).

Novel Drug Delivery Systems in Cancer Therapy Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Novel Drug Delivery Systems in Cancer Therapy Market

Overview of the regional outlook of the Novel Drug Delivery Systems in Cancer Therapy Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Novel Drug Delivery Systems in Cancer Therapy Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Novel Drug Delivery Systems in Cancer Therapy Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Embolization Particles

                2. Nanoparticles

7. Market scenario by region, sub-region, and country.
8. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
9. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
10. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Novel Drug Delivery Systems in Cancer Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Novel Drug Delivery Systems in Cancer Therapy Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.